Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis

  • Lisa E. Gralinski
    Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
  • Timothy P. Sheahan
    Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
  • Thomas E. Morrison
    Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA
  • Vineet D. Menachery
    Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
  • Kara Jensen
    Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
  • Sarah R. Leist
    Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
  • Alan Whitmore
    Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA
  • Mark T. Heise
    Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA
  • Ralph S. Baric
    Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA

説明

<jats:p>The complement system is a critical part of host defense to many bacterial, viral, and fungal infections. It works alongside pattern recognition receptors to stimulate host defense systems in advance of activation of the adaptive immune response. In this study, we directly test the role of complement in SARS-CoV pathogenesis using a mouse model and show that respiratory disease is significantly reduced in the absence of complement even though viral load is unchanged. Complement-deficient mice have reduced neutrophilia in their lungs and reduced systemic inflammation, consistent with the observation that SARS-CoV pathogenesis is an immune-driven disease. These data suggest that inhibition of complement signaling might be an effective treatment option following coronavirus infection.</jats:p>

収録刊行物

  • mBio

    mBio 9 (5), 2018-11-07

    American Society for Microbiology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ